hydrazine and sp2509
hydrazine has been researched along with sp2509 in 11 studies
Research
Studies (11)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Bearss, D; Bhalla, KN; Devaraj, SG; Fiskus, W; Iyer, SP; Liu, K; Portier, BP; Shah, B; Sharma, S | 1 |
| Drakulic, S; Golas, MM; Inui, K; Jayaprakash, S; Le, LTM; Sander, B; Yuan, J; Zhao, Z | 1 |
| He, Z; Hu, Y; Huang, P; Li, Y; Liu, J; Liu, P; Lu, W; Wang, J; Wen, S | 1 |
| Beck, JF; Becker, S; Ebert, F; Lauterjung, ML; Marx, C; Sonnemann, J; Zimmermann, M | 1 |
| Alumkal, JJ; Bankhead, A; Bearss, J; Beer, TM; Berry, DL; Bisson, WH; Coleman, DJ; Gao, L; Haque, R; Heiser, LM; Joshi, SK; Kallakury, BVS; Kim, DH; King, CJ; McWeeney, SK; Sampson, DA; Schwartzman, J; Sehrawat, A; Sharma, S; Thomas, GV; Urrutia, J; Van Den Eeden, SK; Wang, Y; Weinmann, S | 1 |
| Lin, NM; Wu, LW; Zhang, C; Zhang, JK; Zhang, ZY; Zhou, DM; Zhu, HJ | 1 |
| Brohl, AS; Cubitt, CL; Fridley, B; Kahen, E; Reed, DR; Welch, D | 1 |
| Cowan, SP; DeLuca, NA; Dembowski, JA; Harancher, MR; Packard, JE | 1 |
| Guo, Y; He, N; Li, R; Lu, L; Wang, J; Wu, L; Zhang, L; Zhang, X; Zhen, H; Zhou, M | 1 |
| Sun, Y; Wang, H; Wang, J; Zhang, X; Zhang, Z; Zhao, D | 1 |
| Ao, S; Guo, H; Huang, G; Jiang, A; Mao, L; Sang, Y; Sun, X; Tao, J; Wu, W; Xu, C | 1 |
Other Studies
11 other study(ies) available for hydrazine and sp2509
| Article | Year |
|---|---|
Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.
Topics: Animals; Apoptosis; Cells, Cultured; Co-Repressor Proteins; Disease Models, Animal; Enzyme Inhibitors; Female; Histone Acetyltransferases; Histone Demethylases; Histones; Humans; Hydrazines; Leukemia, Myeloid, Acute; Mice, Inbred NOD; Mice, SCID; Nerve Tissue Proteins; Nucleophosmin; RNA, Small Interfering; Stem Cells; Sulfonamides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Stepwise assembly of functional C-terminal REST/NRSF transcriptional repressor complexes as a drug target.
Topics: Acetylation; Animals; Benzamides; Cell Nucleus; Enhancer Elements, Genetic; Histones; Humans; Hydrazines; Multiprotein Complexes; Neoplasm Proteins; Protein Domains; Repressor Proteins; Sf9 Cells; Spodoptera; Sulfonamides | 2017 |
Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Synergism; Energy Metabolism; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Epigenesis, Genetic; Female; Histone Demethylases; Histones; HL-60 Cells; Humans; Hydrazines; Leukemia, Myeloid, Acute; Methylation; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Morpholines; Proto-Oncogene Proteins c-bcl-2; Pyridones; Sulfonamides; Time Factors; Tumor Cells, Cultured; Up-Regulation; Xenograft Model Antitumor Assays | 2018 |
LSD1 (KDM1A)-independent effects of the LSD1 inhibitor SP2509 in cancer cells.
Topics: Animals; Histone Demethylases; Humans; Hydrazines; Leukemia, Myeloid, Acute; Mice; Neoplasm Proteins; Sulfonamides; THP-1 Cells; Xenograft Model Antitumor Assays | 2018 |
LSD1 activates a lethal prostate cancer gene network independently of its demethylase function.
Topics: Cell Survival; Gene Regulatory Networks; Histone Demethylases; Humans; Hydrazines; Male; Neoplasm Proteins; Prostatic Neoplasms, Castration-Resistant; Sulfonamides; Trans-Activators | 2018 |
Suppression of LSD1 enhances the cytotoxic and apoptotic effects of regorafenib in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histone Demethylases; Humans; Hydrazines; Kaplan-Meier Estimate; Liver Neoplasms; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Pyridines; Serine; Sulfonamides; Tranylcypromine | 2019 |
Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cyclophosphamide; Depsipeptides; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Etoposide; Histone Deacetylase Inhibitors; Histone Deacetylases; Histone Demethylases; Humans; Hydrazines; Irinotecan; Sarcoma, Ewing; Sulfonamides; Vincristine | 2019 |
Antiviral Properties of the LSD1 Inhibitor SP-2509.
Topics: Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; DNA Replication; DNA, Viral; Gene Expression Regulation, Viral; Genes, Immediate-Early; Herpes Simplex; Herpesvirus 1, Human; Histone Demethylases; Histones; Humans; Hydrazines; Promoter Regions, Genetic; Sulfonamides; Vero Cells; Virus Replication | 2020 |
SP2509, an inhibitor of LSD1, exerts potential antitumor effects by targeting the JAK/STAT3 signaling.
Topics: A549 Cells; Antineoplastic Agents; Histone Demethylases; Humans; Hydrazines; Janus Kinases; Neoplasm Proteins; Neoplasms; Signal Transduction; STAT3 Transcription Factor; Sulfonamides | 2021 |
Intermolecular insights into allosteric inhibition of histone lysine-specific demethylase 1.
Topics: Allosteric Regulation; Enzyme Inhibitors; Histone Demethylases; Humans; Hydrazines; Models, Molecular; Molecular Structure; Sulfonamides | 2021 |
SP2509, a Selective Inhibitor of LSD1, Suppresses Retinoblastoma Growth by Downregulating β-catenin Signaling.
Topics: beta Catenin; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Histone Demethylases; Humans; Hydrazines; Lysine; Retinal Neoplasms; Retinoblastoma; Signal Transduction; Sulfonamides | 2022 |